Mood Stabilizers during Pregnancy: Clinical Updates
Based on current data of in utero exposure to mood stabilizers, valproic acid (Depakene, Depakote, and others) and carbamazepine (Tegretol and others) present the greatest risk for adverse long-term neurobehavioral outcomes, whereas lithium and lamotrigine (Lamictal and others) so far appear to be safe. Antipsychotics have not been adequately studied.
Ongoing Treatment for BDD
Of patients with body dysmorphic disorder who respond to initial treatment with selective serotonin reuptake inhibitors (SSRIs), those who are continued on SSRI treatment for 6 months show greater improvement and longer time to relapse than those switched to placebo.
FDA Removes Black Box Warning for Smoking Cessation Drugs Varenicline and Bupropion; Low Levels of Brain-Derived Neurotrophic Factor Decrease Depressed Patients Response to Chemotherapy
Antihypertensives and the Risk of Mood Disorders
In a Scottish retrospective study, patients who took angiotensin antagonist antihypertensive medications had a lower risk of being admitted to the hospital for a mood disorder than those who did not.
Download a Sample Issue of BTP
A following sample issue of Biological Therapies in Psychiatry is available in .pdf format. These files require Adobe Acrobat© Reader to view. (If you do not currently have the Acrobat Reader, click here to download).
One, two and three-year subscriptions are immediately available. Each subscription allows you full online access to current and recent issues, a searchable online database, downloadable audio files, and a printed newsletter that will be mailed to you monthly. You'll receive timely, accurate information at a very reasonable price. A one-year US subscription is only $90.00.